Treating cachexia using soluble ACVR2B improves survival, alters mTOR localization, and attenuates liver and spleen responses

Treating cachexia using soluble ACVR2B improves survival, alters mTOR localization, and attenuates liver and spleen responses

Abstract Background Cancer cachexia increases morbidity and mortality, and blocking of activin receptor ligands has improved survival in experimental cancer. However, the underlying mechanisms have not yet been fully uncovered. Methods The effects of blocking activin receptor type 2 (ACVR2) ligands...

Full description

Bibliographic Details
Main Authors: Tuuli A. Nissinen, Jaakko Hentilä, Fabio Penna, Anita Lampinen, Juulia H. Lautaoja, Vasco Fachada, Tanja Holopainen, Olli Ritvos, Riikka Kivelä, Juha J. Hulmi
Format: Article
Language:English
Published: Wiley 2018-06-01
Series:Journal of Cachexia, Sarcopenia and Muscle
Subjects:
Activin
Myostatin
MDSC
Protein synthesis
Acute phase response
Physical activity
Online Access:https://doi.org/10.1002/jcsm.12310

Internet

https://doi.org/10.1002/jcsm.12310

Similar Items